Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.122
-0.020 (-1.75%)
At close: Jul 25, 2025, 4:00 PM
1.160
+0.038 (3.39%)
After-hours: Jul 25, 2025, 6:54 PM EDT

Company Description

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis.

The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial.

Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.
Enlivex Therapeutics logo
CountryIsrael
Founded2005
IPO DateDec 12, 1995
IndustryBiotechnology
SectorHealthcare
Employees71
CEOOren Hershkovitz

Contact Details

Address:
14 Einstein Street
Ness Ziona, 7403618
Israel
Phone972 2 620 8072
Websiteenlivex.com

Stock Details

Ticker SymbolENLV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000919794
CUSIP NumberM4130Y106
ISIN NumberIL0011319527
Employer ID95-4102687
SIC Code7372

Key Executives

NamePosition
Dr. Oren Hershkovitz Ph.D.Chief Executive Officer
Shai Novik M.B.A.Executive Chairman
Prof. Dror Mevorach M.D.Founder and Scientific Advisor
Shachar Shlosberger CPAChief Financial Officer
Dr. Veronique Amor-BaroukhSenior Director of Operations
Sigal AradDirector of Human Resources
Dr. Einat Galamidi M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Oct 3, 200815-12GSecurities registration termination
Oct 3, 20088-KCurrent Report
Oct 2, 200825-NSEFiling
Sep 25, 20088-KCurrent Report
Sep 25, 2008DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2008DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2008425Filing
Sep 5, 20088-KCurrent Report
Sep 5, 2008425Filing
Aug 27, 2008425Filing